Combination Drug Therapy for the Management of Alzheimer’s Disease
Open accessAbstract
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases worldwide. It is the leading cause of dementia in both older and oldest old population. The standard treatment for AD dementia is based on two groups of drugs: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA glutamate receptor modulator memantine. At moderate and severe stages of dementia, it is often necessary to use both a cholinergic inhibitor and memantine simultaneously. This review discusses current capabilities, efficacy and safety of combined therapy for Alzheimer's. It also covers details the features of using fixed combinations of donepezil and memantine in clinical practice.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combination therapies of the pharmacodynamic and pharmacokinetic types are available.
“Combination therapies of the pharmacodynamic and pharmacokinetic types are available.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [219]
Ongoing clinical trials combine novel DMT- or symptomatic-based treatments with standard-of-care medications such as memantine or cholinesterase inhibitors.
“As an illustration, ongoing clinical trials combine novel DMT- or symptomatic-based treatments with standard-of-care medications (such as memantine or cholinesterase inhibitors) [217,218,219].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [219]
Pharmacodynamic agent combinations for AD may consist of DMTs, which change the course of the disease, or symptomatic medicines, which reduce symptoms without changing the course.
“Pharmacodynamic agent combinations for AD may consist of DMTs, which change the course of the disease, or symptomatic medicines, which reduce the symptoms without changing the course of the disease.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [219]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · see citing works
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461 · see citing works
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200 · see citing works
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · see citing works
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523 · see citing works
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 337 · see citing works
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310 · see citing works
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.870517 · Cited by 275 · see citing works
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · see citing works
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165 · see citing works
Howard, R. J., McShane, R. H., Lindesay, J. E. B., Ritchie, C. W., Baldwin, A., Barber, R., Burns, A. S., Dening, T., Findlay, D. M., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 164 · see citing works
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Marie Chupin, A., Hampel, H. J., Lista, S., Cavedo, E., Croisile, B., Louis-Tisserand, G., Touchon, J., Bonafé, A., Ousset, P., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 140 · see citing works
Blanco-Silvente, L., Castells, X., Sáez, M., Barceló, M., Garre-Olmo, J., Vilalta-Franch, J., & Capellà, D. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx012 · Cited by 133 · see citing works
Kobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79 · see citing works
Boustani, M. A., Campbell, N. L., Fox, C., Ayub, A., Farlow, M. R., & Maidment, I. D. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s4250 · Cited by 73 · see citing works
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 61 · see citing works
Araki, T., Wake, R., Miyaoka, T., Kawakami, K., Nagahama, M., Furuya, M., Limoa, E., Liaury, K., Hashioka, S., Murotani, K., et al. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4074 · Cited by 57 · see citing works
Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
Knorz, A. L., & Quante, A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211044746 · Cited by 43 · see citing works
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17 · see citing works
Hendrix, S. B., Ellison, N., Stanworth, S., Otcheretko, V., & Tariot, P. N. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.66 · Cited by 11 · see citing works
Combined therapy for Alzheimer's disease
Zakharov, V. V., Борисовна, Л. А., & Васильевна, В. Н. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-3-74-80 · Cited by 11 · see citing works
Smolyarchuk, Е. А., & Leykin, Z. N. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212203185 · Cited by 6 · see citing works
Ткачева, О. Н., Рунихина, Н. К., Mkhitaryan, E. A., Koberskaya, N. N., & Маневич, Т. М. (2020) · Russian neurological Journal · doi:10.30629/2658-7947-2019-24-5-54-60 · Cited by 3 · see citing works
Self-citationCapabilities of combined therapy of Alzheimer’s disease
Васенина, Е. Е., Veryugina, N. I., & Levin, O. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212211245 · Cited by 1 · see citing works
Колыхалов, И. В., Mkhitaryan, E. A., Fedorova, Y. B., Пономарева, Е. В., Селезнева, Н. Д., Cherdak, M. A., Dudchenko, N. G., Seyfedinova, A. B., Isaev, R. I., Si, G., et al. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312312169 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev. 2018;6:1-245. https://doi.org/10.1002/14651858.CD001190.pub3 · DOI · Paper page
- Ткачева О.Н., Рунихина Н.К., Мхитарян Э.А., Коберская Н.Н., Маневич Т.М. Сравнительный анализ эффективности при- менения монотерапии донепезилом и комбинированной тера- пии донепезилом и акатинолом мемантином у больных с бо- лезнью Альцгеймера на стадии легкой деменции. Российский неврологический журнал. 2019; 24(5):54-60.
- Смолярчук Е.А, Лейкин З.Н. Сравнительное клини- ческое исследование фармакокинетики и биоэквивалентно- сти комбинированного лекарственного препарата Миореол и совместного применения монопрепаратов, содержащих донепезил и мемантин. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122(3):85-91.
- Колыхалов И.В., Мхитарян Э.А., Федорова Я.Б., Пономарева Е.В., Селезнева Н.Д., Чердак М.А., Дудченко Н.Г., Сейфединова А.Б., Исаев Р.И., Гаврилова С.И., Ткачева О.Н. опыт применения комбинации фиксированных доз донепезила и мемантина в терапии болезни Альцгеймера в рамках наблюдательной неинтервенционной много- центровой программы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123(12):69-75.
Cited by
Sorted by citations
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“As an illustration, ongoing clinical trials combine novel DMT-or symptomatic-based treatments with standard-of-care medications (such as memantine or cholinesterase inhibitors) [217–219].”
Method
- Authors
- Dudchenko, N. G., & Mkhitaryan, E. A.
- Affiliations
- Pirogov Russian National Research Medical University (RU)
- Venue
- Russian Journal of Geriatric Medicine
- Publisher
- Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology
- Published
- 2024-06-30
- Issue
- 2
- Pages
- 140-144
- ISSN
- 2686-8636 (ISSN-L)
- 2686-8709
- OpenAlex
- W4401034498
- Cited by
- 2
- References
- 26
- Citations by year
- 2025: 1 · 2024: 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Russian Journal of Geriatric Medicine (publishedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, cholinesterase inhibitors, memantine, donepezil, rivastigmine, galantamine, fixed-dose combination, dementia treatment, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
